Aprogen Biologics

At a glance

Aprogen Biologics filed 80 disclosures in the last 12 months, including 26 5% holder, 11 insider and 6 issuance. The most recent key filing was on Oct 30: A major holder's stake rose from 91.63% to 91.72% (conversion/exercise).

Revenue for 2025 was ₩73.2B, up 8.7% on 2024. It made an operating loss of ₩60.4B. Debt was 111% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩44.7B and operating loss of ₩31.1B.

The 2025 annual report lists 445 employees with an average tenure of 4.1 years and average pay of ₩47.4M, #1571 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩154M each on average. It paid no cash dividend for 2025. ㈜에이프로젠 and related parties held 56.88% at year end.

Of 3 recent 5%+ holder reports, 1 raised and 2 cut a stake; the largest stake reported was 91.72% on Oct 30.

From the 2025 annual report

Staff: 445 (239 men, 206 women), of whom 36 on fixed-term contracts. Total pay for the year: ₩20.9B. Directors and auditors: 5, paid ₩770.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜에이프로젠 holds 56.87%; with 2 related parties the group holds 56.88% of common shares at year end.

Auditor: 대성회계법인 (구, 대성삼경회계법인) · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports